Cargando…

Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats

BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Toshikazu, Zhang, Erquan, Omori, Ayaka, Kabwe, Jane, Kawai, Masako, Maruyama, Junko, Okada, Amphone, Yokochi, Ayumu, Sawada, Hirofumi, Mitani, Yoshihide, Maruyama, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/
https://www.ncbi.nlm.nih.gov/pubmed/34801000
http://dx.doi.org/10.1186/s12890-021-01710-4
_version_ 1784602208299384832
author Ito, Toshikazu
Zhang, Erquan
Omori, Ayaka
Kabwe, Jane
Kawai, Masako
Maruyama, Junko
Okada, Amphone
Yokochi, Ayumu
Sawada, Hirofumi
Mitani, Yoshihide
Maruyama, Kazuo
author_facet Ito, Toshikazu
Zhang, Erquan
Omori, Ayaka
Kabwe, Jane
Kawai, Masako
Maruyama, Junko
Okada, Amphone
Yokochi, Ayumu
Sawada, Hirofumi
Mitani, Yoshihide
Maruyama, Kazuo
author_sort Ito, Toshikazu
collection PubMed
description BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic hypoxia (CH)-induced PH development in rats. METHODS: Fifty-one male Sprague–Dawley rats were fed rat chow with (0.3% CLZ) or without CLZ for 21 days after a single injection of MCT (60 mg/kg) or saline. Forty-eight rats were fed rat chow with and without CLZ for 14 days under ambient or hypobaric (air at 380 mmHg) CH exposure. The mean pulmonary artery pressure (mPAP), the right ventricle weight-to-left ventricle + septum weight ratio (RV/LV + S), percentages of muscularized peripheral pulmonary arteries (%Muscularization) and medial wall thickness of small muscular arteries (%MWT) were assessed. Levels of the endothelial nitric oxide synthase (eNOS), phosphorylated eNOS (peNOS), AKT, pAKT and IκB proteins in lung tissue were measured using Western blotting. Monocyte chemotactic protein (MCP)-1 mRNA in lung tissue was also assessed. RESULTS: mPAP [35.1 ± 1.7 mmHg (MCT) (n = 9) vs. 16.6 ± 0.7 (control) (n = 9) (P < 0.05); 29.1 ± 1.5 mmHg (CH) (n = 10) vs. 17.5 ± 0.5 (control) (n = 10) (P < 0.05)], RV/LV + S [0.40 ± 0.01 (MCT) (n = 18) vs. 0.24 ± 0.01 (control) (n = 10) (P < 0.05); 0.41 ± 0.03 (CH) (n = 13) vs. 0.27 ± 0.06 (control) (n = 10) (P < 0.05)], and %Muscularization and %MWT were increased by MCT injection and CH exposure. CLZ significantly attenuated these changes in the MCT model [mPAP 25.1 ± 1.1 mmHg (n = 11) (P < 0.05), RV/LV + S 0.30 ± 0.01 (n = 14) (P < 0.05)]. In contrast, these CLZ effects were not observed in the CH model. Lung eNOS protein expression was unchanged in the MCT model and increased in the CH model. Lung protein expression of AKT, phosphorylated AKT, and IκB was downregulated by MCT, which was attenuated by CLZ; the CH model did not change these proteins. Lung MCP-1 mRNA levels were increased in MCT rats but not CH rats. CONCLUSIONS: We found model differences in the effect of CLZ on PH development. CLZ might exert a preventive effect on PH development in an inflammatory PH model but not in a vascular structural change model of PH preceded by vasoconstriction. Thus, the preventive effect of CLZ on PH development might depend on the PH etiology.
format Online
Article
Text
id pubmed-8605570
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86055702021-11-22 Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats Ito, Toshikazu Zhang, Erquan Omori, Ayaka Kabwe, Jane Kawai, Masako Maruyama, Junko Okada, Amphone Yokochi, Ayumu Sawada, Hirofumi Mitani, Yoshihide Maruyama, Kazuo BMC Pulm Med Research Article BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic hypoxia (CH)-induced PH development in rats. METHODS: Fifty-one male Sprague–Dawley rats were fed rat chow with (0.3% CLZ) or without CLZ for 21 days after a single injection of MCT (60 mg/kg) or saline. Forty-eight rats were fed rat chow with and without CLZ for 14 days under ambient or hypobaric (air at 380 mmHg) CH exposure. The mean pulmonary artery pressure (mPAP), the right ventricle weight-to-left ventricle + septum weight ratio (RV/LV + S), percentages of muscularized peripheral pulmonary arteries (%Muscularization) and medial wall thickness of small muscular arteries (%MWT) were assessed. Levels of the endothelial nitric oxide synthase (eNOS), phosphorylated eNOS (peNOS), AKT, pAKT and IκB proteins in lung tissue were measured using Western blotting. Monocyte chemotactic protein (MCP)-1 mRNA in lung tissue was also assessed. RESULTS: mPAP [35.1 ± 1.7 mmHg (MCT) (n = 9) vs. 16.6 ± 0.7 (control) (n = 9) (P < 0.05); 29.1 ± 1.5 mmHg (CH) (n = 10) vs. 17.5 ± 0.5 (control) (n = 10) (P < 0.05)], RV/LV + S [0.40 ± 0.01 (MCT) (n = 18) vs. 0.24 ± 0.01 (control) (n = 10) (P < 0.05); 0.41 ± 0.03 (CH) (n = 13) vs. 0.27 ± 0.06 (control) (n = 10) (P < 0.05)], and %Muscularization and %MWT were increased by MCT injection and CH exposure. CLZ significantly attenuated these changes in the MCT model [mPAP 25.1 ± 1.1 mmHg (n = 11) (P < 0.05), RV/LV + S 0.30 ± 0.01 (n = 14) (P < 0.05)]. In contrast, these CLZ effects were not observed in the CH model. Lung eNOS protein expression was unchanged in the MCT model and increased in the CH model. Lung protein expression of AKT, phosphorylated AKT, and IκB was downregulated by MCT, which was attenuated by CLZ; the CH model did not change these proteins. Lung MCP-1 mRNA levels were increased in MCT rats but not CH rats. CONCLUSIONS: We found model differences in the effect of CLZ on PH development. CLZ might exert a preventive effect on PH development in an inflammatory PH model but not in a vascular structural change model of PH preceded by vasoconstriction. Thus, the preventive effect of CLZ on PH development might depend on the PH etiology. BioMed Central 2021-11-20 /pmc/articles/PMC8605570/ /pubmed/34801000 http://dx.doi.org/10.1186/s12890-021-01710-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ito, Toshikazu
Zhang, Erquan
Omori, Ayaka
Kabwe, Jane
Kawai, Masako
Maruyama, Junko
Okada, Amphone
Yokochi, Ayumu
Sawada, Hirofumi
Mitani, Yoshihide
Maruyama, Kazuo
Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title_full Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title_fullStr Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title_full_unstemmed Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title_short Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
title_sort model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/
https://www.ncbi.nlm.nih.gov/pubmed/34801000
http://dx.doi.org/10.1186/s12890-021-01710-4
work_keys_str_mv AT itotoshikazu modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT zhangerquan modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT omoriayaka modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT kabwejane modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT kawaimasako modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT maruyamajunko modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT okadaamphone modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT yokochiayumu modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT sawadahirofumi modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT mitaniyoshihide modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats
AT maruyamakazuo modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats